[REVISION HISTORY]

GLP-1 obesity drug rollout and market expansion

Updated 17 times since CLSTR started tracking revisions of this situation.

What changed

2026-09-07 07:14 UTC → 2026-09-11 08:56 UTC · added ~~removed~~

Novo Nordisk continues to expand its GLP-1 market presence, maintaining approximately a 43% global market share for obesity and diabetes treatments despite competition from Eli Lilly. The oral Wegovy pill remains a primary growth driver, generating approximately $500 million in revenue during the second quarter, up from $350 million in the first quarter. In the U.S., the pill has captured roughly 90% of the oral obesity market with over 5 million prescriptions. As of September 1, 2026, Germany has become the first European Union country to commercialize the oral semaglutide formulation of Wegovy. ~~The daily tablet is indicated for adults with obesity or overweight accompanied by weight-related conditions. Retail prices in Germany~~ Expansion efforts are ~~expected to be comparable to the injectable version, typically ranging between €170 and €280 depending on dosage. Medical professionals note that~~ now reaching Mexico, where the ~~medication requires a prescription and strict administration on an empty stomach.~~ company has received permission from Cofepris to introduce oral semaglutide tablets. To ~~maintain its market position,~~ support this, Novo Nordisk ~~is advancing several projects, including CagriSema, Cagrilintide, and Zenagamtide.~~ plans to increase clinical study funding in Mexico from 1 billion to over 3 billion Mexican pesos. The ~~company~~ impact of GLP-1 use is also ~~securing specific patents, such as formulations with very low or no phenol content~~ being observed in ~~the U.S., and has taken legal action to defend its intellectual property, including obtaining an injunction~~ consumer behavior; in ~~the Netherlands against the sale of an unauthorized semaglutide nasal spray.~~ Mexico, households with at least one user reduced high-calorie product purchases by 20% over six months. Financial outlooks remain ~~divided. Deutsche Bank downgraded the company from ‘hold’ to ‘sell’, lowering its price target from 290 to 265 DKK due to concerns over stagnant revenue and competition. Conversely,~~ cautious. While Erste Group Bank increased its FY2026 earnings per share estimate to ~~$3.46. Following~~ $3.46, other analysts have issued downgrades. Morgan Stanley downgraded the ~~Wegovy pill launch in Germany, Novo Nordisk shares experienced~~ company to ‘Underweight’ with a ~~slight decline~~ 250 DKK price target, citing concerns over mid-term growth and a heavy revenue dependency on semaglutide, which faces patent expiration in ~~New York trading, reflecting investor scrutiny regarding~~ the ~~intensifying competitive landscape. The consensus rating remains ‘hold’. In Denmark, qualitative research~~ early 2030s. This follows a previous downgrade by Deutsche Bank from ~~the University of Southern Denmark highlights social challenges for users.~~ ‘hold’ to ‘sell’.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.